Clinical Trials Logo

Strabismus clinical trials

View clinical trials related to Strabismus.

Filter by:

NCT ID: NCT04285177 Enrolling by invitation - Strabismus Clinical Trials

Choroidal and Retinal Thickness Following Strabismus Surgery

Start date: February 15, 2020
Phase:
Study type: Observational

Prospective study, conducted at Tanta University Ophthalmology Department Measurement of macular and choroidal thickness before and after strabismus surgery

NCT ID: NCT04261699 Completed - Surgery Clinical Trials

One-stage Adjustable Strabismus Surgery Under AIVOC

AIVOC
Start date: January 28, 2020
Phase:
Study type: Observational

The purpose of this study is to note that one-stage adjustable surgery can be enough to provide satisfactory results for the correction of strabismus in adults thanks to the use of an anesthesia type AIVOC (Target-controlled infusion of Propofol-Remifentanyl)

NCT ID: NCT04213768 Not yet recruiting - Strabismus Clinical Trials

Lateral Rectus Resection Versus Lateral Rectus Plication in Patients With Residual Esotropia

Start date: December 2019
Phase: N/A
Study type: Interventional

In this study, the surgical outcomes of lateral rectus plication and resection techniques on patients with residual esotropia will be compared. Methods: In this randomized clinical trial, a total of 57 patients with residual esotropia (31 females and 26 males) who were candidate for lateral rectus resection are going to be included and randomized into plication and resection groups. The inclusion criteria will be residual esotropia after uni- or bilateral medial rectus recession, or unilateral recession and resection (R&R). Subjects with a history of prematurity, lack of central fixation, extraocular muscle palsy, systemic, ocular disorders, follow up less than three months will be excluded. A comprehensive ophthalmic examinations are going to be conducted preoperatively and at 1, 3 and 6 months' follow-ups. Surgical success rate will be considered in cases with a postoperative eso- or exotropia ≤10pd.

NCT ID: NCT04213053 Recruiting - Strabismus Clinical Trials

Lees Screen in Concomitant Strabismus

Start date: July 1, 2020
Phase: N/A
Study type: Interventional

Preoperative and postoperative Lees screen was done after concomitant horizontal strabismus surgery to detect any limitation in the field of operated muscle

NCT ID: NCT04199286 Completed - Strabismus Clinical Trials

Bilateral and Unilateral Horizontal Strabismus Surgery

Start date: December 21, 2019
Phase: N/A
Study type: Interventional

This study was done in alternating strabismus patients to compare symmetrical muscle surgery and asymmetrical one as regard efficacy and lateral incomitance after surgery

NCT ID: NCT04195711 Completed - Strabismus Clinical Trials

Comparative Validation of "Blinq" and "2WIN" Vision Screeners

Start date: November 18, 2019
Phase:
Study type: Observational [Patient Registry]

After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.

NCT ID: NCT04156763 Terminated - Strabismus Clinical Trials

Virtual Reality Test of Strabismus

Start date: June 22, 2020
Phase:
Study type: Observational

Strabismus, or squint, describes any misalignment of the eyes, and can affect both children and adults. As a result, the images of the outside world conveyed to the brain from the two eyes do not correspond, which can result in diplopia, or 'double vision'. As well as impacting on a patient's functionality, strabismus can have cosmetic and psychosocial ramifications. Furthermore, if left untreated in childhood, strabismus can lead to life-long visual impairment, despite best spectacle correction. Current treatment is guided by the exact nature of the strabismus and the patient's age; options include spectacle prescription to correct underlying refractive error, use of prisms to control deviation, or in certain cases, surgery. In order to investigate the size and type of strabismus present, and determine the best management, tests of ocular deviation are performed in Eye Clinics. Quantitative objective assessment of the angle of horizontal and vertical strabismus is currently performed using the prism cover test - the patient is asked to look at a fixation target, and prisms of increasing power are placed in front of one eye until the ocular deviation is neutralised (i.e. there is no movement of the eyes to take up fixation). The test can provide accurate numerical recordings to aid in monitoring and surgical planning. However, the prism cover test requires a range of different prisms, the presence of a near and distance fixation target, a trained examiner, and a patient able to fixate at an appropriate target without moving their head for the duration of the test. In this study, it will be investigated whether a virtual reality headset-based test can produce comparable measurements of ocular deviation to the traditional prism cover test, without the need for prisms, or control of head posture.

NCT ID: NCT04060771 Recruiting - Anesthesia Clinical Trials

Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery

Start date: August 1, 2018
Phase: Phase 3
Study type: Interventional

Background: Postoperative nausea and vomiting (PONV) is one of the main causes of patient and family dissatisfaction, which may delay the onset of oral intake and postpone discharge. In pediatric patients, the incidence of PONV is high, and in some studies it can reach values of 70%. Strabismus surgery is considered an independent risk factor for PONV. Palonosetron is a second generation antiemetic drug, 5-hydroxytryptamine receptor antagonist, with a long half-life, which allows single dose administration and has been shown to be safe and effective in the treatment of chemotherapy induced nausea and vomiting, and has been used with satisfactory results in the prophylaxis of PONV in adult and pediatric patients. Studies involving palonosetron are still scarce.

NCT ID: NCT04054479 Completed - PONV Clinical Trials

Penehyclidine for PONV Prophylaxis After Strabismus Surgery

Start date: July 20, 2019
Phase: Phase 4
Study type: Interventional

Patients scheduled for elective strabismus surgery under general anesthesia in the First Affiliated Hospital of Nanjing Medical University will be included in this study. Patients 1)ASA I or II, 2)aged 3-65 years, 3)scheduled for elective strabismus surgery under general anesthesia, will be included in the study. Patients 1)had prior PONV, 2)severe motion sickness, 3)a history of ophthalmic surgery, 4)had received drugs known to have antiemetic effects, will be excluded from the study. The primary aim is to evaluate the prophylaxis effect of penehyclidine(a novel long acting selective anticholinergic agent developed in China) on postoperative nausea and vomiting after strabismus surgery. Secondary outcomes include the effect of PONV risk factors and surgical technique on PONV rank score, occurance of oculocardiac reflex, time to extubation.

NCT ID: NCT03919708 Withdrawn - Amblyopia Clinical Trials

Amblyopia and Strabismus Detection Using Retinal Birefringence Imaging

RBI
Start date: February 4, 2020
Phase:
Study type: Observational

The purpose of this project is to compare the accuracy of two products at detecting amblyopia and strabismus in children. The devices will be Rebiscan's "blinq" (Pediatric Vision Scanner; PVS) and Rebiscan's RBI (Retinal Birefringence Imager).